Tri Locum Partners’s Axsome Therapeutics AXSM Stock Holding History

Tri Locum Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.5M	Sell	62,116 -139,511	-69%	-$24.1M	1.47%	16
2025 Q4	$36.8M	Sell	201,627 -90,510	-31%	-$12.6M	4.78%	11
2025 Q3	$35.5M	Buy	292,137 +134,276	+85%	+$15.1M	8.16%	4
2025 Q2	$16.5M	Buy	157,861 +56,621	+56%	+$6M	5%	10
2025 Q1	$11.8M	Sell	101,240 -148,529	-59%	-$16.9M	6.06%	7
2024 Q4	$21.1M	Buy	249,769 +158,048	+172%	+$14.5M	4.38%	7
2024 Q3	$8.24M	Sell	91,721 -214,792	-70%	-$18.7M	1.97%	17
2024 Q2	$24.7M	Buy	306,513 +203,802	+198%	+$15.1M	6.24%	6
2024 Q1	$8.2M	Sell	102,711 -28,027	-21%	-$2.35M	2.84%	16
2023 Q4	$10.4M	Sell	130,738 -11,772	-8%	-$787K	4.76%	10
2023 Q3	$9.96M	Sell	142,510 -57,570	-29%	-$4.3M	3.18%	10
2023 Q2	$14.4M	Buy	200,080 +50,875	+34%	+$3.75M	5.34%	6
2023 Q1	$9.2M	Sell	149,205 -50,849	-25%	-$3.34M	2.8%	12
2022 Q4	$15.4M	Buy	+200,054	New	+$12M	6.24%	4

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tri Locum Partners's AXSM Position: Q1 2026 in Review

Tri Locum Partners reduced its Axsome Therapeutics (AXSM) stake by 69% in Q1 2026, selling an estimated $24.1M and leaving 62,116 shares worth $10.5M. The position accounts for 1.47% of the portfolio, ranked #16.

Tri Locum Partners first reported a position in AXSM in Q4 2022 and has held it in 14 quarters since. The position peaked at $36.8M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Tri Locum Partners held 62,116 shares of Axsome Therapeutics worth $10.5M as of Q1 2026.
Tri Locum Partners sold 139,511 Axsome Therapeutics shares in Q1 2026, an estimated $24.1M.
Axsome Therapeutics made up 1.47% of Tri Locum Partners's portfolio in Q1 2026, its #16 holding.
Tri Locum Partners first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 14 quarters since.
Tri Locum Partners's Axsome Therapeutics position peaked at $36.8M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Tri Locum Partners's 13F filing for Q1 2026, filed 18 May 2026.